The company plans to resume its CATT1 Phase 3 trial for type 1 diabetes after submitting a protocol amendment.
High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary endpoint with statistical ...
A revolutionary new drug trial called LION aims to ravage the ... a cancer immunologist from the Cancer Research UK Manchester Institute, University of Manchester. With plans to recruit 89 ...
12d
Clinical Trials Arena on MSNPersica’s antibiotic-based drug alleviates lower back pain in Phase Ib trialEvidence has shown that 25% of patients with chronic lower back pain could be suffering from an infection in the disc space.
10d
Clinical Trials Arena on MSNMerck KGaA’s lupus drug fails in SLE cohort of Phase II trialMerck KGaA’s oral TLR7/8 inhibitor enpatoran has failed to meet the primary endpoint in a subgroup of patients, but ...
The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results